EUR 3.92
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 31.84 Million EUR | -2.32% |
2022 | 32.59 Million EUR | 0.31% |
2021 | 32.49 Million EUR | 18.87% |
2020 | 27.33 Million EUR | 42.74% |
2019 | 19.15 Million EUR | -2.72% |
2018 | 19.68 Million EUR | 14.68% |
2017 | 17.16 Million EUR | 46.73% |
2016 | 11.7 Million EUR | 8.58% |
2015 | 10.77 Million EUR | 3.84% |
2014 | 10.37 Million EUR | 6.46% |
2013 | 9.74 Million EUR | -7.5% |
2012 | 10.53 Million EUR | -4.27% |
2011 | 11 Million EUR | -3.69% |
2010 | 11.42 Million EUR | 2.33% |
2009 | 11.16 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 Q4 | 31.84 Million EUR | 0.0% |
2023 Q2 | 32.32 Million EUR | 0.0% |
2023 FY | 31.84 Million EUR | -2.32% |
2022 Q4 | 32.59 Million EUR | 0.0% |
2022 Q2 | 31.28 Million EUR | 0.0% |
2022 FY | 32.59 Million EUR | 0.31% |
2021 Q2 | 30.36 Million EUR | 0.0% |
2021 FY | 32.49 Million EUR | 18.87% |
2021 Q4 | 32.49 Million EUR | 0.0% |
2020 Q2 | 24.84 Million EUR | 0.0% |
2020 Q4 | 27.33 Million EUR | 0.0% |
2020 FY | 27.33 Million EUR | 42.74% |
2019 Q2 | 19.31 Million EUR | 0.0% |
2019 Q4 | 19.15 Million EUR | 0.0% |
2019 FY | 19.15 Million EUR | -2.72% |
2018 Q2 | 18.38 Million EUR | 0.0% |
2018 FY | 19.68 Million EUR | 14.68% |
2018 Q4 | 19.68 Million EUR | 0.0% |
2017 Q4 | 17.16 Million EUR | 0.0% |
2017 Q2 | 16.9 Million EUR | 0.0% |
2017 FY | 17.16 Million EUR | 46.73% |
2016 Q4 | 11.7 Million EUR | 0.0% |
2016 Q2 | 10.96 Million EUR | 0.0% |
2016 FY | 11.7 Million EUR | 8.58% |
2015 FY | 10.77 Million EUR | 3.84% |
2015 Q2 | 9.85 Million EUR | 0.0% |
2015 Q4 | 10.77 Million EUR | 0.0% |
2014 Q4 | 10.37 Million EUR | 0.0% |
2014 Q2 | 10.16 Million EUR | 0.0% |
2014 FY | 10.37 Million EUR | 6.46% |
2013 Q2 | 10.24 Million EUR | 0.0% |
2013 Q4 | 9.74 Million EUR | 0.0% |
2013 FY | 9.74 Million EUR | -7.5% |
2012 FY | 10.53 Million EUR | -4.27% |
2012 Q4 | 10.53 Million EUR | 0.0% |
2012 Q2 | 11.08 Million EUR | 0.0% |
2011 FY | 11 Million EUR | -3.69% |
2011 Q4 | 11 Million EUR | 0.0% |
2011 Q2 | 11.93 Million EUR | 0.0% |
2010 FY | 11.42 Million EUR | 2.33% |
2010 Q4 | 11.42 Million EUR | 0.0% |
2010 Q2 | 10.62 Million EUR | 0.0% |
2009 Q4 | 11.16 Million EUR | 0.0% |
2009 Q2 | 10.2 Million EUR | 0.0% |
2009 FY | 11.16 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ABIONYX Pharma SA | 14.71 Million EUR | -116.468% |
ABIVAX Société Anonyme | 327.06 Million EUR | 90.264% |
Adocia SA | 24.95 Million EUR | -27.594% |
Aelis Farma SA | 26.28 Million EUR | -21.161% |
Biophytis S.A. | 11.93 Million EUR | -166.776% |
Advicenne S.A. | 12.4 Million EUR | -156.648% |
IntegraGen SA | 8 Million EUR | -298.012% |
Medesis Pharma S.A. | 1.92 Million EUR | -1553.003% |
Neovacs S.A. | 47.53 Million EUR | 33.011% |
NFL Biosciences SA | 3.97 Million EUR | -701.948% |
Plant Advanced Technologies SA | 14.91 Million EUR | -113.522% |
Quantum Genomics Société Anonyme | 3.74 Million EUR | -749.862% |
Sensorion SA | 46.49 Million EUR | 31.513% |
Theranexus Société Anonyme | 7.23 Million EUR | -339.949% |
TME Pharma N.V. | 2.49 Million EUR | -1178.297% |
Valbiotis SA | 33.24 Million EUR | 4.228% |
TheraVet SA | 7.53 Million EUR | -322.638% |
Valerio Therapeutics Société anonyme | 35.27 Million EUR | 9.728% |
argenx SE | 4.11 Billion EUR | 99.226% |
BioSenic S.A. | 9.55 Million EUR | -233.114% |
Celyad Oncology SA | 16.28 Million EUR | -95.568% |
DBV Technologies S.A. | 165.65 Million USD | 80.777% |
Galapagos NV | 4.35 Billion EUR | 99.269% |
Genfit S.A. | 173.87 Million EUR | 81.686% |
GeNeuro SA | 6.31 Million EUR | -404.402% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | 33.218% |
Innate Pharma S.A. | 184.19 Million EUR | 82.712% |
Inventiva S.A. | 69.13 Million EUR | 53.944% |
MaaT Pharma SA | 42.93 Million EUR | 25.829% |
MedinCell S.A. | 36.94 Million EUR | 13.818% |
Nanobiotix S.A. | 93.89 Million EUR | 66.088% |
Onward Medical N.V. | 43.62 Million EUR | 27.016% |
Oryzon Genomics S.A. | 106.9 Million EUR | 70.213% |
OSE Immunotherapeutics SA | 81.9 Million EUR | 61.12% |
Oxurion NV | 6.55 Million EUR | -386.143% |
Pharming Group N.V. | 426.33 Million EUR | 92.531% |
Poxel S.A. | 4.82 Million EUR | -560.219% |
GenSight Biologics S.A. | 9.08 Million EUR | -250.417% |
Transgene SA | 45.21 Million EUR | 29.579% |
Financière de Tubize SA | 1.92 Billion EUR | 98.342% |
UCB SA | 15.53 Billion EUR | 99.795% |
Valneva SE | 469.39 Million EUR | 93.216% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | -3.287% |